Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03993873 · ClinicalTrials.gov registry record · Phase 1

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Turning Point Therapeutics.

Active
Registry status
Phase 1
Development phase
95
Enrollment target
20
Study locations

NCT03993873 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors that is active but no longer recruiting, run by Turning Point Therapeutics. The registered enrollment target is 95 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03993873, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Turning Point Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
95 participants
Enrollment target
20
Study locations

Study Summary

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumors MET Gene Alterations

Interventions

  • DRUG elzovantinib (TPX-0022)

Study Locations (20)

Other

  • Local Institution - 4201 - Lyon
  • Local Institution - 6304 - Seoul
  • Local Institution - 6303 - Seoul
  • Local Institution - 6302 - Seoul

California

  • Local Institution - 2102 - La Jolla
  • Local Institution - 2108 - Orange

Massachusetts

  • Local Institution - 2107 - Boston
  • Local Institution - 2109 - Boston

Michigan

  • Local Institution - 2106 - Ann Arbor
  • Local Institution - 2113 - Detroit

Val-de-Marne

  • Local Institution - 4203 - Saint-Mandé
  • Local Institution - 4204 - Villejuif

Colorado

  • Local Institution - 2105 - Denver

Illinois

  • Local Institution - 2111 - Chicago

Missouri

  • Local Institution - 2103 - St Louis

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2019-09-05
Est. Completion 2027-03-03
Phase Phase 1

Sponsor

Turning Point Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03993873

The ClinicalTrials.gov registry entry for NCT03993873 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower). The listed sponsor is Turning Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which elzovantinib (TPX-0022) is the first listed.

NCT03993873 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03993873 about?

NCT03993873 is a clinical study titled "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET". A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

What is the current status of trial NCT03993873?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2019-09-05. Estimated completion is 2027-03-03.

What conditions does trial NCT03993873 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations.

What interventions are being tested in trial NCT03993873?

The interventions under investigation include: elzovantinib (TPX-0022) (DRUG).

Who is sponsoring clinical trial NCT03993873?

This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03993873 being conducted?

This trial has 20 study locations across California, Colorado, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.